SCHEMBL646225

SCHEMBL646225

O=Cc1cc2c(cc1O)CCC2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ ERN1 O75460 5/20 0.41
▸ POLA1 P09884 2/20 0.40
▸ ESR2 Q92731 1/20 0.38
▸ TYR P14679 2/20 0.37
▸ TRIM24 O15164 2/20 0.37
▸ TRIM33 Q9UPN9 2/20 0.37
▸ CYP19A1 P11511 1/20 0.37
▸ ADCY6 O43306 1/20 0.37
▸ ADCY3 O60266 1/20 0.37
▸ ADCY9 O60503 1/20 0.37
▸ ADCY5 O95622 1/20 0.37
▸ ADCY8 P40145 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29442662 1.00 MEN1 (0.43) MEN1KMT2AKDM4EALDH1A1GAA
SCHEMBL29442689 0.96 KDM4E (0.48) MEN1KMT2AKDM4EALDH1A1GAA
SCHEMBL1506593 0.96 KDM4E (0.48) MEN1KMT2AKDM4EALDH1A1GAA
SCHEMBL14609231 0.84 MEN1 (0.43) MEN1KMT2AKDM4EALDH1A1GAA
SCHEMBL17037970 0.79 POLA1 (0.39) MEN1KMT2AKDM4EALDH1A1GAA
SCHEMBL14925144 0.77 ADCY6 (0.52) ADCY6ADCY3ADCY9ADCY5ADCY8
SCHEMBL14925149 0.77 ADCY6 (0.52) ADCY6ADCY3ADCY9ADCY5ADCY8
SCHEMBL2819831 0.77 HRH3 (0.43) POLA1ACHE
SCHEMBL10597541 0.76 ERN1 (0.52) ERN1TRIM24TRIM33
Bromide SCHEMBL14917356 0.76 ADCY6 (0.50) ADCY6ADCY3ADCY9ADCY5ADCY8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559504-B2 Benzotriazole derivative UBE CORPORATION (JP) 2026-02-24 — — US disclosed
EP-3978073-B1 1H-BENZO[D][1,2,3]TRIAZOLE DERIVATIVES AS KEAP1 INHIBITORS FOR THE TREATMENT OF RENAL DISEASES UBE CORP (JP) 2025-10-15 — — EP disclosed
US-20220259223-A1 BENZOTRIAZOLE DERIVATIVE UBE INDUSTRIES, LTD. (JP) 2022-08-18 — — US disclosed
US-20220259223-A1 BENZOTRIAZOLE DERIVATIVE UBE INDUSTRIES, LTD. (JP) 2022-08-18 — — US disclosed
EP-3978073-A1 BENZOTRIAZOLE DERIVATIVE Ube Industries, Ltd. (JP) 2022-04-06 — — EP disclosed
CN-114174289-A Benzotriazole derivatives 宇部兴产株式会社 2022-03-11 — — CN disclosed
WO-2020241853-A1 BENZOTRIAZOLE DERIVATIVE 宇部興産株式会社 2020-12-03 — — WO disclosed
US-9230827-B2 Method for forming a resist under layer film and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2016-01-05 — — US disclosed
US-9230827-B2 Method for forming a resist under layer film and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2016-01-05 — — US disclosed
US-9046764-B2 Resist underlayer film composition, method for producing polymer for resist underlayer film, and patterning process using the resist underlayer film composition SHIN-ETSU CHEMICAL CO., LTD. (JP) 2015-06-02 — — US disclosed
US-20080293776-A1 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) NOVARTIS AG (CH) 2008-11-27 — — US disclosed
EP-1963294-A1 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) Novartis AG (CH) 2008-09-03 — — EP disclosed
WO-2007067613-A1 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) NOVARTIS AG (CH) 2007-06-14 — — WO disclosed
CN-1150183-C New heterocyclic tertiary amines, process for their preparation and pharmaceutical compositions containing them ɪά��ʵ���� 2004-05-19 — — CN disclosed
EP-0768307-B1 Heterocyclic tertiary amines, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2003-11-26 — — EP disclosed
US-5726208-A Heterocyclic tertiary amines ADIR ET COMPAGNIE (FR) 1998-03-10 — — US disclosed
CN-1152572-A New heterocyclic tertiary amines, process for their preparation and pharmaceutical compositions containing them ADIR (FR) 1997-06-25 — — CN disclosed
EP-0768307-A1 Heterocyclic tertiary amines, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1997-04-16 — — EP disclosed
US-4600719-A Tetrahydropyridine and piperidine derivatives CIBA GEIGY CORPORATION (US) 1986-07-15 — — US disclosed
US-4210655-A Anti-depressant benzofuranyl piperidines CIBA-GEIGY CORPORATION (US) 1980-07-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559504-B2 Benzotriazole derivative KEAP1, NFE2L2, NCOR1 MEN1 3532/4885KMT2A 347/4885KDM4E 502/4885
US-20080293776-A1 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) PTPRS, PTPN5, PTPRR MEN1 3927/4885KMT2A 2549/4885KDM4E 2554/4885
US-20220259223-A1 BENZOTRIAZOLE DERIVATIVE KEAP1, NFE2L2, BACH1 MEN1 3589/4885KMT2A 111/4885KDM4E 729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback